MASS

908 Devices Inc.

Fundamental data last updated:June 10, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Devices

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

08/04/2026

Business Summary

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.

 


Analyze MASS on TradingView

VALUATION

P/E

-8.65

Market Cap ($M USD)

$318.79M

Forward P/E

-42.15

PEG

-0.53

PRICE TO SALES

5.52

PRICE TO BOOK

2.31

EV / EBITDA

-13.29

5-Year Average P/E

Free Cash Flow Yield

-2.64%

DCF Value

$-9.75

Graham Number

N/A

Price to FCF

-37.86

EV to FCF

-30.36

Earnings Yield

-11.56%

FCF Yield

-2.64%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.97

Next Year EPS Growth Estimate

-$0.20

Next Year Revenue Growth Estimate

$10.18B

Return on Equity (ROE)

-25.50%

FREE CASH FLOW

Operating Margin

-52.50%

Debt-to-Equity

0.12

Piotroski F-Score

2

Altman Z-Score

2.21

Return on Invested Capital (ROIC)

-20.64%

Current Ratio

3.58

Quick Ratio

3.25

Net Debt to EBITDA

3.28

Interest Coverage

0.00

Gross Profit margin

49.00%

FCF PER SHARE

$-0.23

REVENUE PER SHARE

$1.57

Analyze MASS on TradingView

Gainseekers Quantitative Analysis

Summary

MASS 908 Devices Inc. appears to be a perplexing case of market optimism despite glaring financial weaknesses. The stock has been trading above its DCF value, suggesting a potential mispricing. With a negative Forward P/E and Earnings Yield, the company is far from profitability, raising questions about its growth trajectory. The Altman Z-score of 2.02 signals moderate financial distress, hinting at potential solvency issues. Investors should tread cautiously, as the numbers paint a picture of a company struggling to find its footing.

AI Exposure / Tech Reliance

Operating within the Medical Devices industry, MASS 908 Devices Inc. is well-positioned to leverage AI and tech advancements. The healthcare sector is ripe for innovation, and companies that can integrate AI into their diagnostics and devices stand to gain a competitive edge. This adaptability could be crucial for future growth and resilience.

The Bull Case

For the optimistic investor, MASS 908 Devices Inc. offers a glimmer of hope through its robust Current Ratio of 3.58, indicating strong liquidity. The low Debt/Equity ratio of 0.12 suggests prudent financial management, providing a cushion against economic downturns. Despite a low Piotroski F-Score of 2, the company's ability to maintain a Gross Profit Margin of 51.49% showcases its pricing power. These factors could appeal to those seeking potential turnaround stories in the healthcare sector.

The Bear Case

However, the bear case is hard to ignore. The company's negative EPS and a Forward P/E of -40.85 highlight a dire profitability outlook. Its Price/Sales ratio of 5.34 and Price/Book ratio of 2.24 suggest overvaluation, especially given the negative FCF Yield and ROIC. Trading close to its 52-week high, the stock appears technically overextended, making it a risky bet for cautious investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

N/A

Institutional Ownership %

1-Year Beta

0.57

Insider Buying % (6 Mo)

Distance to 52-Week High

10.79%

Distance to 52-Week Low

40.40%

EARNINGS SURPRISE %

-46.67%

50-DAY SMA

$6.97

200-DAY SMA

$6.73

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.